Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) generates frequent news as a medical technology company focused on obstructive sleep apnea (OSA), snoring and other sleep-related breathing disorders. News about Vivos often centers on its FDA-cleared oral appliance technologies, clinical data releases, acquisitions of sleep centers and collaborations with medical practices that adopt its treatment methods.
Readers following VVOS news can expect regular updates on the company’s Complete Airway Repositioning and/or Expansion (CARE) devices, including the DNA appliance for pediatric OSA and other oral appliances in its portfolio. Vivos has announced multicenter clinical trial results, additional clinical datasets and peer-reviewed publications that it says support the safety and efficacy of its devices in both children and adults. These clinical milestones are a recurring theme in the company’s press releases.
Vivos also issues news about its business model and operations, such as the acquisition of The Sleep Center of Nevada and the rollout of an updated sleep practice affiliation model with partners like MISleep Solutions in Auburn Hills, Michigan. These items describe how Vivos integrates its diagnostic tools and therapies into sleep testing and treatment centers, and how it deploys Sleep Optimization teams to manage patient demand.
In addition, VVOS news includes financial results, conference call announcements, Medicare and CMS PDAC developments related to devices like the VidaSleep oral appliance, and participation in investor or research-focused events. For investors and observers interested in the intersection of sleep medicine, medical devices and healthcare services, the VVOS news feed offers ongoing insight into how Vivos is applying its technologies and partnerships in the OSA treatment landscape.
Vivos Therapeutics (NASDAQ: VVOS) will release its second and third quarter 2022 financial results on December 20, 2022, after market close. The company will hold a conference call at 5:00 pm ET to discuss these results and recent company developments. Vivos has faced delays in filing its Form 10-Q due to technical discussions with accountants. With the filing of these results, Vivos aims to become current in its financial filings for Nasdaq compliance. The company specializes in treatments for dentofacial abnormalities and obstructive sleep apnea.
Vivos Therapeutics announces a strategic collaboration with Nexus Dental Systems expected to boost revenues immediately. This partnership combines Vivos’ out-of-network Billing Intelligence Service with Nexus’ in-network platform, enhancing medical billing access for sleep and breathing disorder treatments. The collaboration aims to improve reimbursement rates and reduce out-of-pocket expenses for patients, potentially increasing case acceptance for Vivos-trained dentists. Vivos currently boasts a 98% success rate for reimbursement claims.
Vivos Therapeutics (NASDAQ: VVOS) announced it expects to become current on its SEC filings soon after receiving a notice from Nasdaq for not timely filing its 10-Q report for Q3 2022. The issue arose from complexities in the company’s revenue recognition policies, specifically ASC Topic 606. Vivos has resolved these matters and restated its 10-Q for Q1 2022. The company intends to file its delayed Q2 and Q3 reports shortly, which will address Nasdaq's concerns. Importantly, this notice does not immediately affect the trading of VVOS stock.
Vivos Therapeutics (NASDAQ: VVOS) announced a review of its revenue recognition policies, concluding that minimal adjustments are needed for prior financial results. The first quarter 2022 revenue is set to increase by about $200,000, with no revenue lost. The company will restate its financials without needing to amend previous audited annual statements. Vivos will file restated Q1 2022 results and anticipates submitting Q2 and Q3 2022 reports by year-end. The adjustments will not impact cash flows or liquidity, ensuring Nasdaq compliance for financial filings.
Vivos Therapeutics (NASDAQ: VVOS) announced it received a compliance notice from Nasdaq for failing to timely file its Form 10-Q for the quarter ended June 30, 2022. This is due to ongoing reviews of financial statements and discussions over revenue recognition policies. The company has 60 days from August 23, 2022, to file the report to regain compliance. If they fail to do so, Nasdaq may initiate suspension and delisting procedures. The company is working to complete the filing as soon as possible.
Vivos Therapeutics (NASDAQ: VVOS) announced a delay in its Q2 2022 financial results, citing a need for a reevaluation of its revenue recognition policy under ASC Topic 606. CEO Kirk Huntsman assured investors that the delay is not indicative of the company's overall health. Despite the delay, Vivos reported strong sales in June with record appliance sales and new provider enrollments. The company is implementing cost-cutting measures and anticipates potential positive cash flow by early 2024.
Vivos Therapeutics (NASDAQ: VVOS) announced the rescheduling of its second quarter financial results originally set for August 15, 2022, due to discussions with its accountants over revenue recognition policies under ASC Topic 606. The new date for the financial results release and conference call is expected on or before August 22, 2022. Vivos specializes in treating dentofacial abnormalities and obstructive sleep apnea through innovative, non-invasive methods.
Vivos Therapeutics (NASDAQ: VVOS) is set to announce its Q2 2022 financial results after market close on August 15, 2022. A conference call will follow at 5:00 PM ET that day to discuss the results and company milestones. Vivos specializes in treatments for dentofacial abnormalities and conditions like obstructive sleep apnea (OSA), with its Vivos Method providing a non-invasive solution to approximately 28,000 patients treated globally. The call can be accessed via dial-in or online webcast, with a replay available until August 29, 2022.
Vivos Therapeutics has received multiple Class I clearances from the Therapeutic Goods Administration in
Vivos Therapeutics (NASDAQ: VVOS) has secured an exclusive distribution agreement with GM Instruments, becoming the sole U.S. and Canadian distributor of the NR6 Rhinomanometer, an FDA-approved device for assessing nasal breathing in patients with sleep and breathing issues. This collaboration is expected to enhance Vivos' revenue stream and competitive positioning by providing dentists with critical tools for evaluating and treating conditions like obstructive sleep apnea (OSA). The agreement marks a significant step in Vivos' commitment to improving patient outcomes through innovative diagnostics.